HER2- and ER/PR+
I have just been given this diagnoise and am looking for info on treatment
Interested in more discussions like this? Go to the Breast Cancer Support Group.
I have just been given this diagnoise and am looking for info on treatment
Interested in more discussions like this? Go to the Breast Cancer Support Group.
I also have IDC er/pr+ HER2- . I am having surgery Thursday. I’m doing the lumpectomy with full reconstruction on both breasts so I guess partial mastectomy. I’m told I will get 16 rounds of RT after that. My mammaprint showed very low risk of recurrence so no chemo.
-
Like -
Helpful -
Hug
3 ReactionsGood luck with your surgery.
-
Like -
Helpful -
Hug
2 ReactionsI am glad that you are well. Wondering why you didn't go with mastectomy. Would you mind sharing?
-
Like -
Helpful -
Hug
2 ReactionsWhat is a mammaprint?
-
Like -
Helpful -
Hug
1 ReactionI guess it looks at the genetics of the cancer and says I’m not a candidate for chemo. Dr said very low risk of reoccurrence. Not sure I understand it completely but she said it only applies to chemo. It’s not a type that would respond to chemo.
-
Like -
Helpful -
Hug
4 ReactionsOncotype Dx and Mammaprint are both genomic tests, which is different from genetic tests. . The genomic tests personalize treatment: give risk of recurrence with and without meds, and whether chemo is of benefit.
-
Like -
Helpful -
Hug
5 ReactionsThe OncotypeDX gives a 'risk of recurrence within 9 years' number, given as a % (probability) of recurrence, conditional upon taking aromatase inhibitors or tamoxifen.
It does not give a probability of recurrence if one declines anti-hormone therapy. One can however calculate that drug-free risk using industry estimates of the benefit of the anti-hormone drugs. The rough calculation would be to double that risk number to get rough idea of added risk of not taking anti-hormone therapy.
15% of people who take the OncotypeDX get a risk score of 3% or less with the majority of those cases also having had cancer-free sentinel lymph node negative biopsies. [I confirmed this number with Exact Sciences, the purveyor of the OncotypeDX, recently as there's misinformation on Mayo Connect stating that 30% of the OncotypeDX tests yield 3% risk of lower. That is incorrect.]
-
Like -
Helpful -
Hug
2 ReactionsI asked Exact Sciences about the risk of 'spread' versus recurrence since the OncotypeDX (the test I had) doesn't specifically predict that. The answer is interesting and the person in the science section whom I spoke with is sending me more info. But, basically, the same TaylorRX data pool from which Oncotype based much of its algorithm (not a good explanation but to keep things simple) also included 'spread' as well as recurrence statistics. Inferentially, a low risk of distant recurrence correlates with, also, a low risk for spread from cancer site assuming clean margins. Cancer-free lymph nodes lowers that risk further. If only we could get 100% perfect data, decisions would be so much easier, sigh. But at least we have better tools than women even 20 years ago.
-
Like -
Helpful -
Hug
4 ReactionsThank you.
-
Like -
Helpful -
Hug
2 ReactionsHope it helps. I had a lot of help decoding the science and research studies when I faced a decision last year as a science-trained friend worked meticulously to sort it all out for his wife the year before when a routine mammo and ultrasound found a Stage 1 breast cancer tumor resting near her chest wall.
She had a lumpectomy, very low OncotypeDX probability of recurrence, and clean sentinel lymph nodes so faced the same decision tree. I benefitted from their intense research and analysis.
-
Like -
Helpful -
Hug
1 Reaction